Business Description
Athira Pharma Inc
NAICS : 541714
SIC : 2833
ISIN : US04746L1044
Share Class Description:
ATHA: Ordinary SharesDescription
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 93.01 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -26.5 | |||||
| 3-Year EPS without NRI Growth Rate | -24.5 | |||||
| 3-Year FCF Growth Rate | -6.4 | |||||
| 3-Year Book Growth Rate | -26.1 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.98 | |||||
| 9-Day RSI | 30.46 | |||||
| 14-Day RSI | 33.68 | |||||
| 6-1 Month Momentum % | 65.58 | |||||
| 12-1 Month Momentum % | -7.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.37 | |||||
| Quick Ratio | 5.37 | |||||
| Cash Ratio | 5.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.5 | |||||
| Shareholder Yield % | 0.31 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -64.22 | |||||
| ROA % | -56.36 | |||||
| ROIC % | -466.91 | |||||
| ROC (Joel Greenblatt) % | -2562.62 | |||||
| ROCE % | -68.75 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.56 | |||||
| Price-to-Tangible-Book | 0.56 | |||||
| EV-to-EBIT | 0.54 | |||||
| EV-to-EBITDA | 0.55 | |||||
| EV-to-FCF | 0.68 | |||||
| Price-to-Net-Current-Asset-Value | 0.59 | |||||
| Price-to-Net-Cash | 0.63 | |||||
| Earnings Yield (Greenblatt) % | 185.19 | |||||
| FCF Yield % | -137.32 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers